| scholarly article | Q13442814 |
| P50 | author | Kevin J Horgan | Q56797386 |
| Jørn Herrstedt | Q93260680 | ||
| Hyman B Muss | Q104758257 | ||
| Paul J Hesketh | Q114369492 | ||
| Harry Raftopoulos | Q114369494 | ||
| Steven M Grunberg | Q114369495 | ||
| Munir Gabriel | Q114369496 | ||
| Carolyn M Hustad | Q114369497 | ||
| Franck Skobieranda | Q114369498 | ||
| P2093 | author name string | Anthony Rodgers | |
| Peter D Eisenberg | |||
| David G Warr | |||
| Aprepitant Moderately Emetogenic Chemotherapy Study Group | |||
| P2860 | cites work | Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology | Q33880234 |
| Delayed emesis: moderately emetogenic chemotherapy | Q35953416 | ||
| Acute emesis: moderately emetogenic chemotherapy | Q35964110 | ||
| Consensus proposals for the prevention of acute and delayed vomiting and nausea following high-emetic-risk chemotherapy. | Q35964114 | ||
| Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity--an update. | Q35984417 | ||
| Granisetron compared with prednisolone plus metopimazine as anti-emetic prophylaxis during multiple cycles of moderately emetogenic chemotherapy | Q36617964 | ||
| Analysis of cumulative probabilities shows that the efficacy of 5HT3 antagonist prophylaxis is not maintained | Q36799686 | ||
| Proposal for classifying the acute emetogenicity of cancer chemotherapy | Q41314646 | ||
| Ondansetron plus metopimazine compared with ondansetron plus metopimazine plus prednisolone as antiemetic prophylaxis in patients receiving multiple cycles of moderately emetogenic chemotherapy | Q43562737 | ||
| Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America | Q44464294 | ||
| The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 St | Q44618271 | ||
| The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical | Q44744702 | ||
| Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy | Q46443858 | ||
| Antiemetic activity of high doses of metoclopramide combined with methylprednisolone versus metoclopramide alone in cisplatin-treated cancer patients: a randomized double-blind trial of the Italian Oncology Group for Clinical Research. | Q52612776 | ||
| Comparison of dexamethasone and ondansetron in the prophylaxis of emesis induced by moderately emetogenic chemotherapy | Q61868395 | ||
| Ondansetron compared with metoclopramide in the control of emesis and quality of life during repeated chemotherapy for breast cancer | Q67547487 | ||
| The pattern of emesis following high-dose cyclophosphamide and the anti-emetic efficacy of ondansetron | Q71698818 | ||
| ESMO Recommendations for prophylaxis of chemotherapy-induced nausea and vomiting (NV) | Q74585768 | ||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | chemotherapy | Q974135 |
| prevention | Q1717246 | ||
| P304 | page(s) | 1548-1555 | |
| P577 | publication date | 2005-10-01 | |
| P1433 | published in | Cancer | Q326041 |
| P1476 | title | Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy | |
| P478 | volume | 104 |
| Q84640968 | Acute emesis: moderately emetogenic chemotherapy |
| Q53239014 | Addition of aprepitant improves protection against cisplatin-induced emesis when a conventional anti-emetic regimen fails. |
| Q34588516 | An update on palonosetron hydrochloride for the treatment of radio/chemotherapy-induced nausea and vomiting |
| Q86928599 | Anti-emetics in paediatric patients receiving chemotherapy |
| Q37355479 | Antiemetic therapy options for chemotherapy-induced nausea and vomiting in breast cancer patients. |
| Q37039597 | Antiemetics: an update and the MASCC guidelines applied in clinical practice |
| Q36673972 | Aprepitant for prevention of nausea and vomiting secondary to high-dose cyclophosphamide administered to patients undergoing autologous peripheral blood stem cells mobilization: a phase II trial. |
| Q45163008 | Aprepitant triple therapy for the prevention of chemotherapy-induced nausea and vomiting following high-dose cisplatin in Chinese patients: a randomized, double-blind, placebo-controlled phase III trial |
| Q37589613 | Aprepitant: a review of its use in the prevention of nausea and vomiting |
| Q34450534 | Aprepitant: the evidence for its place in the prevention of chemotherapy-induced nausea and vomiting. |
| Q36925594 | Blocking neurogenic inflammation for the treatment of acute disorders of the central nervous system. |
| Q36064834 | Chemotherapy-Induced Nausea and Vomiting: Time for More Emphasis on Nausea? |
| Q40143472 | Choice of study endpoint significantly impacts the results of breast cancer trials evaluating chemotherapy-induced nausea and vomiting |
| Q38123245 | Cisplatin : an old drug with a newfound efficacy -- from mechanisms of action to cytotoxicity |
| Q89260280 | Corticosteroids, the oldest agent in the prevention of chemotherapy-induced nausea and vomiting: What about the guidelines? |
| Q46927060 | Cost-effectiveness analysis of aprepitant in the prevention of chemotherapy-induced nausea and vomiting in Belgium |
| Q37091366 | Cost-effectiveness of an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer in the UK |
| Q37609798 | Current pharmacotherapy for chemotherapy-induced nausea and vomiting in cancer patients |
| Q34289628 | Daily palonosetron is superior to ondansetron in the prevention of delayed chemotherapy-induced nausea and vomiting in patients with acute myelogenous leukemia |
| Q41644259 | Defining optimal control of chemotherapy-induced nausea and vomiting-based on patients' experience. |
| Q30235971 | Delayed Chemotherapy-Induced Nausea and Vomiting: Pathogenesis, Incidence, and Current Management |
| Q37857329 | Development of aprepitant, the first neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting |
| Q40866626 | Efficacy and safety of fosaprepitant for the prevention of nausea and emesis during 5 weeks of chemoradiotherapy for cervical cancer (the GAND-emesis study): a multinational, randomised, placebo-controlled, double-blind, phase 3 trial. |
| Q44470627 | Efficacy of the neurokinin-1 receptor antagonist aprepitant in children with cyclical vomiting syndrome |
| Q84206278 | Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of phase 3 trial of aprepitant in patients receiving adriamycin-cyclophosphamide-based chemotherapy |
| Q37902946 | Fall in plasma ghrelin concentrations after cisplatin-based chemotherapy in esophageal cancer patients |
| Q92993034 | Fixed combination of oral NEPA (netupitant-palonosetron) for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in patients receiving multiple cycles of chemotherapy: Efficacy data from 2 randomized, double-blind phase III |
| Q34239808 | Fosaprepitant and aprepitant: an update of the evidence for their place in the prevention of chemotherapy-induced nausea and vomiting |
| Q37982438 | Fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting |
| Q37672351 | Fosaprepitant-induced phlebitis: a focus on patients receiving doxorubicin/cyclophosphamide therapy |
| Q39653943 | Infusion site adverse events in breast cancer patients receiving highly emetic chemotherapy with prophylactic anti-emetic treatment with aprepitant and fosaprepitant: A retrospective comparison |
| Q42786722 | Management of chemotherapy-induced nausea and vomiting |
| Q37660556 | NEPA, a fixed oral combination of netupitant and palonosetron, improves control of chemotherapy-induced nausea and vomiting (CINV) over multiple cycles of chemotherapy: results of a randomized, double-blind, phase 3 trial versus oral palonosetron |
| Q36920404 | Nanomedicines in the treatment of emesis during chemotherapy: focus on aprepitant |
| Q90435566 | Netupitant/palonosetron (NEPA) and dexamethasone for prevention of emesis in breast cancer patients receiving adjuvant anthracycline plus cyclophosphamide: a multi-cycle, phase II study |
| Q46336740 | Palonosetron and prednisolone for the prevention of nausea and emesis during fractionated radiotherapy and 5 cycles of concomitant weekly cisplatin-a phase II study. |
| Q36478194 | Personalized Estimate of Chemotherapy-Induced Nausea and Vomiting: Development and External Validation of a Nomogram in Cancer Patients Receiving Highly/Moderately Emetogenic Chemotherapy. |
| Q59104644 | Phase II, open label, randomized comparative trial of ondansetron alone versus the combination of ondansetron and aprepitant for the prevention of nausea and vomiting in patients with hematologic malignancies receiving regimens containing high-dose c |
| Q38290777 | Placebo interventions for nausea: a systematic review |
| Q37636064 | Prevention of chemotherapy induced nausea and vomiting: a focus on aprepitant |
| Q36823546 | Prevention of chemotherapy-induced nausea and vomiting: focus on fosaprepitant |
| Q51466468 | Prospective evaluation of the incidence of delayed nausea and vomiting in patients with colorectal cancer receiving oxaliplatin-based chemotherapy. |
| Q57070792 | Randomized, double-blind trial comparing the antiemetic effect of tropisetron plus metopimazine with tropisetron plus placebo in patients receiving multiple cycles of multiple-day cisplatin-based chemotherapy |
| Q37104814 | Randomized, placebo-controlled, pilot study evaluating aprepitant single dose plus palonosetron and dexamethasone for the prevention of acute and delayed chemotherapy-induced nausea and vomiting |
| Q58828834 | Results of a 7-day aprepitant schedule for the prevention of nausea and vomiting in 5-day cisplatin-based germ cell tumor chemotherapy |
| Q38789806 | Rolapitant for the prevention of delayed nausea and vomiting over initial and repeat courses of emetogenic chemotherapy |
| Q50661502 | SEOM clinical guidelines for the treatment of antiemetic prophylaxis in cancer patients receiving chemotherapy |
| Q85708178 | SEOM guide to antiemetic prophylaxis in cancer patients treated with chemotherapy 2013 |
| Q44165565 | Safety and efficacy of aprepitant, ramosetron, and dexamethasone for chemotherapy-induced nausea and vomiting in patients with ovarian cancer treated with paclitaxel/carboplatin |
| Q37854702 | Safety evaluation of aprepitant for the prevention of chemotherapy-induced nausea and vomiting |
| Q38109245 | Safety of neurokinin-1 receptor antagonists |
| Q36607177 | Substance P as a novel anti-obesity target |
| Q37638682 | Tachykinin receptor antagonists in clinical trials |
| Q36548740 | The neurokinin1 receptor antagonist aprepitant as an antiemetic for moderately emetogenic chemotherapy |
| Q37503489 | Treatment of Nausea and Vomiting During Chemotherapy. |
| Q38060202 | Use of PD biomarkers to drive dose selection and early clinical decision making |
| Q34417851 | Use of granisetron transdermal system in the prevention of chemotherapy-induced nausea and vomiting: a review |
Search more.